

John H Sampson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2444550/john-h-sampson-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330
papers

22,275
citations

80
h-index

139
g-index

359
ext. papers

25,722
ext. citations

5.8
avg. IF

6.72
L-index

#	Paper	IF	Citations
330	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4722-9	2.2	1119
329	Phase II trial of gefitinib in recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 133-42	2.2	607
328	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4722-9	2.2	593
327	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1373-1385	21.7	518
326	Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. <i>Cancer Research</i> , 2006 , 66, 3294-302	10.1	430
325	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , 2015 , 16, e534-e542	21.7	425
324	Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. <i>Journal of Neurosurgery</i> , 1998 , 88, 11-20	3.2	401
323	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018 , 379, 150-161	59.2	363
322	Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2010 , 12, 871-81	1	338
321	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015 , 519, 366-9	50.4	333
320	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1003-1010	13.4	328
319	Proteomic and immunologic analyses of brain tumor exosomes. <i>FASEB Journal</i> , 2009 , 23, 1541-57	0.9	315
318	Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9359-68	2.2	286
317	Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 10-8	1	285
316	Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 837-44	2.2	285
315	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 509-520	19.4	284
314	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro-Oncology</i> , 2015 , 17, 854-61	1	257

313	Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. <i>Nature Medicine</i> , 2018 , 24, 1459-1468	50.5	253
312	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011 , 13, 324-331	1	241
311	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015 , 11, 504-14	15	240
310	Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. <i>Clinical Cancer Research</i> , 2007 , 13, 2158-67	12.9	235
309	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. <i>Neuro-Oncology</i> , 2018 , 20, 674-686	1	233
308	Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1262-7	2.2	226
307	Phase II trial of temozolomide in patients with progressive low-grade glioma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 646-51	2.2	218
306	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2773-9	6.1	209
305	Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1389-97	2.2	206
304	EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. <i>Clinical Cancer Research</i> , 2014 , 20, 972-84	12.9	205
303	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003 , 65, 27-35	4.8	198
302	Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. <i>Neurosurgery</i> , 2005 , 56, 546-59; discussion 546-59	3.2	198
301	Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. <i>Cancer Research</i> , 2002 , 62, 3335-9	10.1	189
300	Poor drug distribution as a possible explanation for the results of the PRECISE trial. <i>Journal of Neurosurgery</i> , 2010 , 113, 301-9	3.2	186
299	Convection-enhanced delivery of therapeutics for brain disease, and its optimization. <i>Neurosurgical Focus</i> , 2006 , 20, E12	4.2	177
298	Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7178-87	2.2	174
297	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020 , 20, 12-25	31.3	174
296	Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. <i>Clinical Cancer Research</i> , 2006 , 12, 860-8	12.9	173

295	Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors. <i>Radiology</i> , 2006 , 240, 793-802	20.5	173
294	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010 , 96, 219-30	4.8	172
293	Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. <i>Clinical Cancer Research</i> , 2003 , 9, 4247-54	12.9	163
292	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. <i>Neuro-Oncology</i> , 2008 , 10, 320-9	1	160
291	Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 7503-8	11.5	160
290	Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. <i>Neurosurgery</i> , 2012 , 70, 234-43; discussion 243-4	3.2	159
289	Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2277-83	2.2	156
288	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. <i>Clinical Cancer Research</i> , 2017 , 23, 1898-1909	12.9	152
287	Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. <i>Clinical Cancer Research</i> , 2008 , 14, 7068-73	12.9	152
286	Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2004 , 10, 3216-24	12.9	137
285	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014 , 16, 1441-58	1	136
284	Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. <i>Seminars in Immunology</i> , 2008 , 20, 267-75	10.7	133
283	Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 2018-24	12.9	132
282	Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. <i>Clinical Cancer Research</i> , 2006 , 12, 4294-305	12.9	132
281	Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). <i>Clinical Cancer Research</i> , 2002 , 8, 3496-502	12.9	120
280	Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 419-27	7.4	119
279	The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. <i>Clinical Cancer Research</i> , 2011 , 17, 4119-24	12.9	119
278	Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. <i>Neurosurgery</i> , 2007 , 61, 1031-7; discussion 1037-8	3.2	114

277	Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3522-8	2.2	111
276	Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. <i>Journal of Neuroimmunology</i> , 2000 , 103, 16-25	3.5	109
275	Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 155-64	4.8	108
274	EGFRvIII-targeted vaccination therapy of malignant glioma. <i>Brain Pathology</i> , 2009 , 19, 713-23	6	107
273	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 57-66	4.8	104
272	Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. <i>Neuro-Oncology</i> , 2007 , 9, 343-53	1	101
271	Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance. <i>Neurosurgery</i> , 2004 , 54, 884-9; discussion 889-90	3.2	100
270	Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. <i>Neuro-Oncology</i> , 2008 , 10, 98-103	1	98
269	A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. <i>Clinical Cancer Research</i> , 2008 , 14, 5759-68	12.9	97
268	Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4202-4210	12.9	96
267	Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 270-5 ^{11.5}		95
266	A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 414-27	7.3	95
265	Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 73, 1369-75	4	93
264	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011 , 13, 353-61 ¹		90
263	Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 100-8	4	88
262	Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans. <i>Blood</i> , 2011 , 118, 3003-12	2.2	87
261	Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007 , 83, 53-60	4.8	87
260	Poliovirus receptor CD155-targeted oncolysis of glioma. <i>Neuro-Oncology</i> , 2004 , 6, 208-17	1	87

259	Intracerebral delivery of a third generation EGFRVIII-specific chimeric antigen receptor is efficacious against human glioma. <i>Journal of Clinical Neuroscience</i> , 2014 , 21, 189-90	2.2	85
258	EGFRVIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. <i>PLoS ONE</i> , 2014 , 9, e94281	3.7	85
257	Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. <i>Operative Neurosurgery</i> , 2007 , 60, ONS89-98; discussion ONS98-9	1.6	85
256	A pilot study of IL-2R blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. <i>PLoS ONE</i> , 2012 , 7, e31046	3.7	84
255	Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. <i>Neuro-Oncology</i> , 2011 , 13, 3-13	1	84
254	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017 , 13, 363-374	15	82
253	Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 873-9	4	82
252	Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. <i>Journal of Neurosurgery</i> , 2008 , 109, 874-80	3.2	82
251	Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. <i>Journal of Clinical Investigation</i> , 2014 , 124, 5352-67	15.9	82
250	Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. <i>Neurosurgery</i> , 1997 , 41, 1365-72; discussion 1372-3	3.2	79
249	IMCT-19.COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM). <i>Neuro-Oncology</i> , 2015 , 17, v111.4-v112	1	78
248	PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2019 , 21, vi185-vi185	1	78
247	ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2019 , 21, vi8-vi8	1	78
246	EXTH-09. FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019 , 21, vi84-vi84	1	78
245	DDIS-02. NOVEL BISPECIFIC ACTIVATOR OF MACROPHAGES FOR THE TREATMENT OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi69-vi69	1	78
244	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. <i>Neuro-Oncology</i> , 2018 , 20, vi7-vi7	1	78
243	RBTT-02. ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL. <i>Neuro-Oncology</i> , 2018 , 20, vi234-vi234	1	78
242	CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL. <i>Neuro-Oncology Advances</i> , 2021 , 3, iv3-iv3	0.9	78

241	Immunotherapy for Brain Tumors. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2450-2456	2.2	73
240	Immunotherapy of malignant brain tumors. <i>Immunological Reviews</i> , 2008 , 222, 70-100	11.3	73
239	Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 371-9	4.8	72
238	Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. <i>Cancer</i> , 2011 , 117, 5351-8	6.4	71
237	Thickness of subcutaneous fat as a risk factor for infection in cervical spine fusion surgery. <i>Journal of Bone and Joint Surgery - Series A</i> , 2013 , 95, 323-8	5.6	70
236	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 54-68	7	70
235	A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. <i>Journal of Neurochemistry</i> , 2009 , 109, 1079-86	6	70
234	Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. <i>Immunotherapy</i> , 2014 , 6, 679-90	3.8	68
233	The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 1087-98	5.4	67
232	IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. <i>International Journal of Cancer</i> , 2009 , 125, 680-7	7.5	67
231	Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. <i>Neurosurgery</i> , 2002 , 50, 158-64; discussion 164-6	3.2	67
230	Bispecific antibodies engage T cells for antitumor immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 843-53	5.4	66
229	Recurrence of a cerebral arteriovenous malformation after surgical excision. Case report. <i>Journal of Neurosurgery</i> , 1996 , 84, 879-82	3.2	66
228	Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. <i>Neurosurgery</i> , 2011 , 69, 668-76	3.2	64
227	Phase II study of Gleevec [®] plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 409-15	4.8	62
226	Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. <i>Neurosurgical Focus</i> , 2006 , 20, E15	4.2	62
225	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. <i>Clinical Cancer Research</i> , 2016 , 22, 582-95	12.9	61
224	Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 58-66	4	61

223	Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. <i>American Journal of Roentgenology</i> , 2007 , 188, 703-9	5.4	61
222	Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 267-77	4.8	60
221	Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma. <i>Neurosurgery</i> , 2002 , 50, 158-166	3.2	60
220	Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. <i>Cancer Treatment Reviews</i> , 2013 , 39, 261-9	14.4	59
219	Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. <i>Clinical Cancer Research</i> , 2014 , 20, 2684-94	12.9	57
218	Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. <i>Clinical Cancer Research</i> , 2006 , 12, 7306-15	12.9	57
217	Rindopepimut with Bevacizumab for Patients with Relapsed EGFRVIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1586-1594	12.9	56
216	Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 5514-20	12.9	54
215	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. <i>Cancer Research</i> , 2018 , 78, 256-264	10.1	53
214	A Supramolecular Vaccine Platform Based on α -Helical Peptide Nanofibers. <i>ACS Biomaterials Science and Engineering</i> , 2017 , 3, 3128-3132	5.5	51
213	Myeloablative temozolomide enhances CD8+ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. <i>PLoS ONE</i> , 2013 , 8, e59082	3.7	50
212	Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2009 , 15, 1064-8	12.9	50
211	Paraganglioma of the head and neck: long-term local control with radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 304-7	2.7	50
210	Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. <i>Neurosurgical Focus</i> , 2006 , 20, E14	4.2	50
209	Are BiTEs the "missing link" in cancer therapy?. <i>OncImmunology</i> , 2015 , 4, e1008339	7.2	49
208	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. <i>Expert Review of Vaccines</i> , 2013 , 12, 597-615	5.2	49
207	The current state of immunotherapy for gliomas: an eye toward the future. <i>Journal of Neurosurgery</i> , 2019 , 131, 657-666	3.2	48
206	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. <i>Clinical Cancer Research</i> , 2020 , 26, 5287-5296	12.9	48

205	Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma. <i>OncImmunology</i> , 2018 , 7, e1434464	7.2	48
204	Oncolytic polio virotherapy of cancer. <i>Cancer</i> , 2014 , 120, 3277-86	6.4	48
203	Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3135-45	15.9	48
202	Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 1049-1060	5.1	47
201	Combating immunosuppression in glioma. <i>Future Oncology</i> , 2008 , 4, 433-42	3.6	47
200	Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. <i>Clinical Cancer Research</i> , 2006 , 12, 1349-54	12.9	47
199	Monoclonal antibody therapy of human gliomas: current status and future approaches. <i>Cancer and Metastasis Reviews</i> , 1999 , 18, 451-64	9.6	46
198	The role of tregs in glioma-mediated immunosuppression: potential target for intervention. <i>Neurosurgery Clinics of North America</i> , 2010 , 21, 125-37	4	45
197	ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2009-2009	2.2	45
196	Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. <i>Journal of Neuro-Oncology</i> , 2010 , 98, 1-7	4.8	44
195	Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. <i>Cancer Immunology Research</i> , 2013 , 1, 163	12.5	43
194	Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions. <i>Journal of Neurosurgery</i> , 2014 , 121, 262-76	3.2	43
193	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. <i>Neuro-Oncology</i> , 2005 , 7, 90-6	1	43
192	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. <i>Clinical Cancer Research</i> , 2019 , 25, 2042-2048	12.9	43
191	Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3010-3010	2.2	42
190	Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. <i>Journal of Immunological Methods</i> , 2008 , 339, 74-81	2.5	41
189	Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. <i>Clinical Cancer Research</i> , 2004 , 10, 4831-8	12.9	41
188	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. <i>Clinical Cancer Research</i> , 2019 , 25, 358-368	12.9	41

187	Contemporary surgical management of vestibular schwannomas: analysis of complications and lessons learned over the past decade. <i>Operative Neurosurgery</i> , 2013 , 72, ons103-15; discussion ons115	1.6	40
186	Dorsal root entry zone lesions for intractable pain after trauma to the conus medullaris and cauda equina. <i>Journal of Neurosurgery</i> , 1995 , 82, 28-34	3.2	40
185	The Evolving Modern Management of Brain Metastasis. <i>Clinical Cancer Research</i> , 2019 , 25, 6570-6580	12.9	38
184	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. <i>Journal of Neuro-Oncology</i> , 2009 , 95, 393-400	4.8	37
183	Immunotherapy approaches for malignant glioma from 2007 to 2009. <i>Current Neurology and Neuroscience Reports</i> , 2010 , 10, 259-66	6.6	37
182	Selective modification of antigen-specific T cells by RNA electroporation. <i>Human Gene Therapy</i> , 2008 , 19, 511-21	4.8	37
181	Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. <i>Oncot Immunology</i> , 2017 , 6, e1256527	7.2	36
180	Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 499-506	4.8	36
179	A novel method for volumetric MRI response assessment of enhancing brain tumors. <i>PLoS ONE</i> , 2011 , 6, e16031	3.7	36
178	EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 115-21	7.4	36
177	Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. <i>Nuclear Medicine and Biology</i> , 2009 , 36, 659-69	2.1	35
176	Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. <i>Neuro-Oncology</i> , 2001 , 3, 246-50	1	35
175	Toward effective immunotherapy for the treatment of malignant brain tumors. <i>Neurotherapeutics</i> , 2009 , 6, 527-38	6.4	33
174	Recurrent malignant gliomas. <i>Seminars in Radiation Oncology</i> , 2014 , 24, 289-98	5.5	32
173	Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. <i>Neurosurgical Review</i> , 2008 , 31, 141-55; discussion 155	3.9	32
172	Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. <i>Neuro-Oncology</i> , 2004 , 6, 134-44	1	32
171	Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 912-8	8.9	32
170	Immunotherapy for malignant glioma. <i>Surgical Neurology International</i> , 2015 , 6, S68-77	1	31

169	A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. <i>Journal of Neuroimmunology</i> , 1997 , 78, 34-46	3.5	31
168	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021 , 12, 352	17.4	31
167	The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. <i>Journal of Neuro-Oncology</i> , 2003 , 64, 161-76	4.8	30
166	Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. <i>Spine</i> , 1995 , 20, 2141-6	3.3	30
165	Single fraction stereotactic radiosurgery for multiple brain metastases. <i>Advances in Radiation Oncology</i> , 2017 , 2, 555-563	3.3	29
164	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. <i>Clinical Cancer Research</i> , 2018 , 24, 3611-3631	12.9	29
163	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. <i>Oncolimmunology</i> , 2015 , 4, e994374	7.2	29
162	ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016 , 18, vi17-vi18	1	29
161	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 133-45	3.7	29
160	Prospect of rindopepimut in the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 507-513	5.4	28
159	Current multidisciplinary management of brain metastases. <i>Cancer</i> , 2020 , 126, 1390-1406	6.4	28
158	Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. <i>Oncolimmunology</i> , 2013 , 2, e26757	7.2	27
157	Peptide vaccines for the treatment of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2015 , 123, 433-40	4.8	26
156	Impact of PhD training on scholarship in a neurosurgical career. <i>Journal of Neurosurgery</i> , 2014 , 120, 730-5.2	5.2	26
155	Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2009 , 11, 556-61	1	26
154	Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model. <i>Journal of Neuroimmunology</i> , 1998 , 86, 46-52	3.5	26
153	A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2079-TPS2079	2.2	26
152	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5297-5303	12.9	26

151	Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. <i>Cancer</i> , 2009 , 115, 2964-70	6.4	25
150	Oncolytic virus-derived type I interferon restricts CAR T cell therapy. <i>Nature Communications</i> , 2020 , 11, 3187	17.4	24
149	Monitoring radiographic brain tumor progression. <i>Toxins</i> , 2011 , 3, 191-200	4.9	23
148	Is cytomegalovirus a therapeutic target in glioblastoma?. <i>Clinical Cancer Research</i> , 2011 , 17, 4619-21	12.9	23
147	Convection enhanced delivery of macromolecules for brain tumors. <i>Current Drug Discovery Technologies</i> , 2012 , 9, 305-10	1.5	23
146	Epidermal growth factor receptor and variant III targeted immunotherapy. <i>Neuro-Oncology</i> , 2014 , 16 Suppl 8, viii20-5	1	22
145	Advances and challenges: dendritic cell vaccination strategies for glioblastoma. <i>Expert Review of Vaccines</i> , 2017 , 16, 27-36	5.2	22
144	Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. <i>Neuro-Oncology</i> , 2017 , 19, 1391-1397	1	21
143	Vaccination strategies for neuro-oncology. <i>Neuro-Oncology</i> , 2015 , 17 Suppl 7, vii15-vii25	1	21
142	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 579-591	5.4	21
141	Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, e739-42	2.2	21
140	Cryptococcal meningitis in patients with glioma: a report of two cases. <i>Journal of Neuro-Oncology</i> , 2008 , 89, 51-3	4.8	21
139	Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2014-2014	2.2	21
138	Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors. <i>Cancer Research</i> , 2016 , 76, 5143-50	10.1	21
137	Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. <i>Journal of Neuro-Oncology</i> , 2021 , 151, 55-62	4.8	21
136	Comparative study of Helical and Sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. <i>Biomaterials Science</i> , 2020 , 8, 3522-3535	7.4	20
135	Delivering therapy to target: improving the odds for successful drug development. <i>Therapeutic Delivery</i> , 2016 , 7, 457-81	3.8	20
134	Clinicopathological characteristics and treatment of rhabdoid glioblastoma. <i>Journal of Neurosurgery</i> , 2013 , 119, 412-9	3.2	20

133	Toxin-based targeted therapy for malignant brain tumors. <i>Clinical and Developmental Immunology</i> , 2012 , 2012, 480429		20
132	Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 695-9	7.3	20
131	A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. <i>Journal of Neurosurgery</i> , 2014 , 121, 536-42	3.2	19
130	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. <i>Future Oncology</i> , 2013 , 9, 977-90	3.6	19
129	Adoptive immunotherapy for malignant glioma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003 , 9, 157-66	2.2	19
128	Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. <i>Neuro-Oncology</i> , 2004 , 6, 145-53	1	19
127	Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. <i>Cancer Immunology, Immunotherapy</i> , 2002 , 50, 639-52	7.4	19
126	Imaging of convection enhanced delivery of toxins in humans. <i>Toxins</i> , 2011 , 3, 201-6	4.9	18
125	Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. <i>Journal of Clinical Investigation</i> , 2020 , 130, 774-788	15.9	18
124	Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells. <i>Journal of Clinical Neuroscience</i> , 2018 , 56, 163-168	2.2	17
123	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. <i>Expert Review of Clinical Pharmacology</i> , 2013 , 6, 375-86	3.8	17
122	IMCT-08ReACT: LONG-TERM SURVIVAL FROM A RANDOMIZED PHASE II STUDY OF RINDOPEPIMUT (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015 , 17, v109.1-v109	1	17
121	Immunological targeting of cytomegalovirus for glioblastoma therapy. <i>OncolImmunology</i> , 2014 , 3, e29289.2		17
120	Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review. <i>Journal of Neurosurgery</i> , 2013 , 118, 1176-80	3.2	17
119	Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic. <i>Drugs of the Future</i> , 2013 , 38, 147-155	2.3	17
118	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. <i>Cancer Research</i> , 2019 , 79, 3383-3394	10.1	16
117	Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. <i>Cancer Immunology Research</i> , 2015 , 3, 320-5	12.5	16
116	Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2047-61	4	16

115	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 277-287	4.1	15
114	107 ReACT. <i>Neurosurgery</i> , 2015 , 62, 198-199	3.2	15
113	A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. <i>Oncolmunology</i> , 2013 , 2, e23639	7.2	15
112	Clinical applications of a peptide-based vaccine for glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2010 , 21, 95-109	4	15
111	Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. <i>Journal of Neuro-Oncology</i> , 1999 , 44, 233-41	4.8	15
110	Solitary eosinophilic granuloma invading the clivus of an adult: case report. <i>Neurosurgery</i> , 1992 , 31, 755-7; discussion 757-8	3.2	15
109	Immunomodulation for glioblastoma. <i>Current Opinion in Neurology</i> , 2017 , 30, 361-369	7.1	14
108	Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 79-94	5.4	14
107	Enzyme redesign guided by cancer-derived IDH1 mutations. <i>Nature Chemical Biology</i> , 2012 , 8, 887-9	11.7	14
106	Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. <i>Journal of Visualized Experiments</i> , 2015 ,	1.6	13
105	Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. <i>Oncolmunology</i> , 2014 , 3, e944054	7.2	13
104	Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 65-74 ⁸	4.8	12
103	BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 983-7	7.4	12
102	How does the immune system attack cancer?. <i>Current Problems in Surgery</i> , 2004 , 41, 15-132	2.8	12
101	Facial pain due to vascular lesions of the brain stem relieved by dorsal root entry zone lesions in the nucleus caudalis. Report of two cases. <i>Journal of Neurosurgery</i> , 1992 , 77, 473-5	3.2	12
100	miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment. <i>Oncolmunology</i> , 2015 , 4, e990803	7.2	11
99	Antibody-based immunotherapy for malignant glioma. <i>Seminars in Oncology</i> , 2014 , 41, 496-510	5.5	11
98	Regulatory T cells move in when gliomas say "I Do". <i>Clinical Cancer Research</i> , 2012 , 18, 6086-8	12.9	11

97	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2061-2061	2.2	11
96	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. <i>Journal of Neurochemistry</i> , 2015 , 133, 730-8	6	10
95	First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach 2020 , 8,		10
94	Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients: Are We Improving?. <i>Neurosurgery</i> , 2018 , 83, 1269-1276	3.2	10
93	Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. <i>Clinical Cancer Research</i> , 2016 , 22, 5164-5166	12.9	9
92	Reply to M.S. Lesniak. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3105-3106	2.2	9
91	Clinical immunotherapy for brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002 , 12, 641-64	3	9
90	Solitary Eosinophilic Granuloma Invading the Clivus of an Adult. <i>Neurosurgery</i> , 1992 , 31, 755-757	3.2	9
89	Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach. <i>Journal of Proteome Research</i> , 2019 , 18, 3032-3041	5.6	8
88	Radiotherapy and radiosurgery for tumors of the central nervous system. <i>Surgical Oncology Clinics of North America</i> , 2013 , 22, 445-61	2.7	8
87	The use of motor mapping to aid resection of eloquent gliomas. <i>Neurosurgery Clinics of North America</i> , 2012 , 23, 215-25, vii	4	8
86	Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 717-32	3.5	8
85	Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321. <i>Neurological Research</i> , 2010 , 32, 810-5	2.7	8
84	A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1649-62	7.4	7
83	Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. <i>Onc Immunology</i> , 2014 , 3, e944059	7.2	7
82	Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. <i>Journal of Neuroimmunology</i> , 2007 , 182, 63-72	3.5	7
81	Viruses in the treatment of brain tumors. <i>Neuroimaging Clinics of North America</i> , 2002 , 12, 553-70	3	7
80	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2068-2068	2.2	7

79	Determinants of Intraparenchymal Infusion Distributions: Modeling and Analyses of Human Glioblastoma Trials. <i>Pharmaceutics</i> , 2020 , 12,	6.4	7
78	Effective effectors: How T cells access and infiltrate the central nervous system. <i>Pharmacology & Therapeutics</i> , 2019 , 197, 52-60	13.9	7
77	IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143. <i>Neuro-Oncology</i> , 2015 , 17, v107.3-v107	1	6
76	Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. <i>Journal of Neuro-Oncology</i> , 2010 , 98, 427-30	4.8	6
75	Cholesterol granuloma of the lateral ventricle. Case report. <i>Journal of Neurosurgery</i> , 2008 , 108, 357-60	3.2	6
74	Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. <i>Neurologia Medico-Chirurgica</i> , 2006 , 46, 485-9; discussion 489-90	2.6	6
73	ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143. <i>Neuro-Oncology</i> , 2016 , 18, vi21-vi21	1	6
72	CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response. <i>OncolImmunology</i> , 2018 , 7, e1502904	7.2	6
71	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 205-11	7.4	5
70	EGFRvIII: an oncogene deletion mutant cell surface receptor target expressed by multiple tumour types. <i>Expert Opinion on Therapeutic Targets</i> , 2000 , 4, 497-514		5
69	Targeting Immunometabolism in Glioblastoma. <i>Frontiers in Oncology</i> , 2021 , 11, 696402	5.3	5
68	Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. <i>Methods in Molecular Biology</i> , 2016 , 1403, 819-38	1.4	5
67	A Review of Anesthesia Simulation in Low-Income Countries. <i>Current Anesthesiology Reports</i> , 2019 , 9, 1-9	1	4
66	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - AuthorsReply. <i>Lancet Oncology, The</i> , 2017 , 18, e709-e710	21.7	4
65	Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. <i>Journal of Immunological Methods</i> , 2013 , 395, 14-20	2.5	4
64	Stereotactic radiosurgery in the treatment of a dural carotid-cavernous fistula. <i>Journal of Neuro-Ophthalmology</i> , 2010 , 30, 138-44	2.6	4
63	The History, Evolution, and Clinical use of Dendritic Cell-Based Immunization Strategies in the Therapy of Brain Tumors. <i>Journal of Neuro-Oncology</i> , 2003 , 64, 161-176	4.8	4
62	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13526-e13526	2.2	4

61	Immunotherapy with tumor vaccines for the treatment of malignant gliomas. <i>Current Drug Discovery Technologies</i> , 2012 , 9, 237-55	1.5	4
60	GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody. <i>PLoS ONE</i> , 2020 , 15, e0236374	3.7	4
59	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021 , 27, 3916-3925	12.9	4
58	A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis. <i>Journal of Immunological Methods</i> , 2018 , 459, 90-93	2.5	4
57	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
56	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
55	MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2039-2039	2.2	3
54	MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2513-2513	2.2	3
53	Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. <i>Journal of Radiosurgery and SBRT</i> , 2014 , 3, 37-42	0.4	3
52	Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma. <i>Cancers</i> , 2021 , 13,	6.6	3
51	Convection-Enhanced Drug Delivery to the Brain. <i>Neuromethods</i> , 2010 , 291-318	0.4	3
50	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1147-1158	3.8	3
49	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. <i>Neuro-Oncology</i> , 2019 , 21, vi7-vi7	1	3
48	ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. <i>Neuro-Oncology</i> , 2019 , 21, vi12-vi12	1	3
47	Accuracy of Novel Computed Tomography-Guided Frameless Stereotactic Drilling and Catheter System in Human Cadavers. <i>World Neurosurgery</i> , 2017 , 106, 757-763	2.1	2
46	Resection of vestibular schwannomas. <i>Journal of Neurosurgery</i> , 2011 , 114, 1216-7; discussion 1217	3.2	2
45	Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e13518-e13518	2.2	2
44	Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13532-e13532	2.2	2

43	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2566-2566	2.2	2
42	Brain Metastases from Malignant Melanoma 2005 , 430-438		2
41	A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope. <i>Npj Vaccines</i> , 2021 , 6, 12	9.5	2
40	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. <i>Neuro-Oncology</i> , 2018 , 20, i93-i93	1	2
39	Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study.. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100760	3.3	2
38	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vdac025 ^{0.9}		2
37	The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. <i>Journal of Neuro-Oncology</i> , 2017 , 132, 83-87	4.8	1
36	Advances in Immunotherapy: Abhijit Guha Award Presentation. <i>Neurosurgery</i> , 2016 , 63 Suppl 1, 85-87	3.2	1
35	Complete response to steroids in dural inflammatory pseudotumor associated with Still@ disease. <i>Journal of Clinical Neuroscience</i> , 2013 , 20, 1445-8	2.2	1
34	The limitations of imaging response criteria. <i>Lancet Oncology, The</i> , 2012 , 13, 1064-5	21.7	1
33	Low-grade glioma. <i>Journal of Neurosurgery</i> , 2011 , 114, 563-4; discussion 564-5	3.2	1
32	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2011 , 29, e519-e520	2.2	1
31	Clinical data simplified. <i>Journal of Neurosurgery</i> , 2012 , 116, 346-8; discussion 348	3.2	1
30	The gravitational shunt: an alternative approach to cerebrospinal fluid shunting. <i>World Neurosurgery</i> , 1993 , 40, 112-8		1
29	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2060-2060	2.2	1
28	For whom the T cells troll? Bispecific T-cell engagers in glioblastoma 2021 , 9,		1
27	Cytokine-Based Gene Therapy for Brain Tumors 1998 , 231-294		1
26	Genetics of glioma1-23		1

25	ATIM-30. COMBATING RECURRENT GLIOBLASTOMA WITH MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, THROUGH MRI-GUIDED CONVECTIVE DELIVERY. <i>Neuro-Oncology</i> , 2019 , 21, vi8-vi8	1	1
24	ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2019 , 21, vi6-vi6	1	1
23	ATIM-05. INTRATUMORAL DELIVERY OF MDNA55, AN INTERLEUKIN-4 RECEPTOR TARGETED IMMUNOTHERAPY, BY MRI-GUIDED CONVECTIVE DELIVERY FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi1-vi2	1	1
22	ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG). <i>Neuro-Oncology</i> , 2018 , 20, vi9-vi9	1	1
21	Immunotherapy for High-Grade Gliomas 2017 , 177-192		
20	Reply to Q Assembling the brain trust: the multidisciplinary imperative in neuro-oncologyQ <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 522-523	19.4	
19	Introduction. Update on adult neuro-oncology. <i>Neurosurgical Focus</i> , 2018 , 44, E1	4.2	
18	Enhanced oncolytic virotherapy through oxidative stress inhibition. <i>Molecular Therapy</i> , 2013 , 21, 1981-3	11.7	
17	Obituary. Robert H. Wilkins, MD, 1934-2017. <i>Journal of Neurosurgery</i> , 2017 , 127, 1457-1458	3.2	
16	Novel Therapeutic Approaches for High-Grade Gliomas. <i>Frontiers in Neuroscience</i> , 2004 , 155-180		
15	The effect of adoptive transfer of ex vivo activated T cells on the efficacy and tumor penetrance of intravenously-administered CD3-engaging bispecific antibody.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 30-30	2.2	
14	Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13030-e13030	2.2	
13	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13533-e13533	2.2	
12	Malignant Glioma Immunotherapy: A Peptide Vaccine from Bench to Bedside 2011 , 349-356		
11	Design and statistical analysis of clinical trials for glioma therapy 169-189		
10	Radiation therapy for gliomas 49-75		
9	Immunotherapy for gliomas 91-120		
8	Neuropathology of gliomas 146-168		

7 Health-related quality of life in glioma patients 190-204

6 Chemotherapy for gliomas 76-90

5 Glioma surgery 24-48

4 Neuroradiology of gliomas 121-145

3 Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy **2021**, 635-665

2 Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors **2018**, 693-705

1 Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype.. *Methods in Molecular Biology*, **2022**, 2410, 609-626 1.4